| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ALCJ Stock Overview
Crossject Société Anonyme develops needle-free injection systems.
Crossject Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.04 |
| 52 Week High | €3.59 |
| 52 Week Low | €1.41 |
| Beta | 1.73 |
| 1 Month Change | 0.25% |
| 3 Month Change | -10.92% |
| 1 Year Change | -18.73% |
| 3 Year Change | 7.37% |
| 5 Year Change | -65.13% |
| Change since IPO | -78.57% |
Recent News & Updates
The Crossject Société Anonyme (EPA:ALCJ) Share Price Has Gained 78% And Shareholders Are Hoping For More
It's been a soft week for Crossject Société Anonyme ( EPA:ALCJ ) shares, which are down 13%. While that might be a...
Shareholder Returns
| ALCJ | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | 1.0% | 2.8% | -1.3% |
| 1Y | -18.7% | -5.9% | -5.4% |
Return vs Industry: ALCJ underperformed the French Medical Equipment industry which returned -5.9% over the past year.
Return vs Market: ALCJ underperformed the French Market which returned -5.4% over the past year.
Price Volatility
| ALCJ volatility | |
|---|---|
| ALCJ Average Weekly Movement | 10.4% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in FR Market | 10.5% |
| 10% least volatile stocks in FR Market | 3.6% |
Stable Share Price: ALCJ is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ALCJ's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 90 | Patrick Alexandre | https://www.crossject.com |
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis.
Crossject Société Anonyme Fundamentals Summary
| ALCJ fundamental statistics | |
|---|---|
| Market Cap | €56.31m |
| Earnings (TTM) | -€10.81m |
| Revenue (TTM) | €6.48m |
8.7x
P/S Ratio-5.2x
P/E RatioIs ALCJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALCJ income statement (TTM) | |
|---|---|
| Revenue | €6.48m |
| Cost of Revenue | €6.69m |
| Gross Profit | -€205.00k |
| Other Expenses | €10.60m |
| Earnings | -€10.81m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | -3.16% |
| Net Profit Margin | -166.76% |
| Debt/Equity Ratio | -425.6% |
How did ALCJ perform over the long term?
See historical performance and comparisonValuation
Is Crossject Société Anonyme undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
In this section, we usually try to help investors determine whether Crossject Société Anonyme is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Crossject Société Anonyme has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Future Growth
How is Crossject Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score
1/6Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-43.3%
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ALCJ's forecast earnings growth is above the savings rate (0.3%).
Earnings vs Market: Insufficient data to determine if ALCJ's earnings are forecast to grow faster than the French market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ALCJ's revenue is expected to decline over the next 3 years (-43.3% per year).
High Growth Revenue: ALCJ's revenue is forecast to decline over the next 3 years (-43.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALCJ's Return on Equity is forecast to be high in 3 years time (35.8%)
Past Performance
How has Crossject Société Anonyme performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-7.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALCJ is currently unprofitable.
Growing Profit Margin: ALCJ is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALCJ is unprofitable, and losses have increased over the past 5 years at a rate of 7.3% per year.
Accelerating Growth: Unable to compare ALCJ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALCJ is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).
Return on Equity
High ROE: ALCJ's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Financial Health
How is Crossject Société Anonyme's financial position?
Financial Health Score
0/6Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ALCJ has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ALCJ has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ALCJ has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ALCJ's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALCJ has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ALCJ has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.7% each year
Dividend
What is Crossject Société Anonyme current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALCJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALCJ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALCJ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALCJ's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALCJ has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.7yrs
Average board tenure
CEO
Patrick Alexandre
21.33yrs
Tenure
€211,280
Compensation
Mr. Patrick Alexandre co-founded Crossject Société Anonyme (f/k/a, Crossject Medical Technology) in 2001 and has been its Chairman of the Executive Board since 2012 and serves as its Chief Executive Office...
Board Members
Experienced Board: ALCJ's board of directors are considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.
Top Shareholders
Company Information
Crossject Société Anonyme's employee growth, exchange listings and data sources
Key Information
- Name: Crossject Société Anonyme
- Ticker: ALCJ
- Exchange: ENXTPA
- Founded: 2001
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: €56.307m
- Shares outstanding: 27.60m
- Website: https://www.crossject.com
Number of Employees
Location
- Crossject Société Anonyme
- 6 Rue Pauline Kergomard
- Dijon
- Burgundy
- 21000
- France
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/23 00:00 |
| End of Day Share Price | 2022/05/23 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.